Biorthex cuts to concentrate on Actipore projects
This article was originally published in Clinica
Biomaterial company Biorthex is to cut around half of its workforce as it restructures to focus on beginning US clinical trials for its Actipore PLF device and the launch of its Actipore ACF device. Biorthex also announced that plans to merge with Ideal Medical Products' subsidiary Scient'x have been abandoned.
You may also be interested in...
The fast-dissolving tablet will launch in early March. Its list price is not available but based on pricing for Allergan’s oral anti-CGRP Ubrelvy, ICER has said Biohaven’s rimegepant is likely to be cost-effective.
A surge in Chinese applications for clinical trials for coronavirus treatments, and a fall in patient numbers, are complicating recruitment efforts for the most promising drugs, prompting official moves to tighten study rules.